Medical devices, healthcare technology and the business of care
PMA approval · P250003

Embrace(TM) Hydrogel Embolic System

Instylla, Inc. · Decision date Aug 5, 2025

MEDTECHLEDGER EXPLANATIONP250003

What did the FDA approve?

FDA approved the Embrace Hydrogel Embolic System from Instylla, Inc. on August 5, 2025 under PMA number P250003. The approval statement describes the device as indicated for embolization of hypervascular tumors in peripheral arteries of 5 mm or larger.

The record identifies the product code QVG and the specialty Cardiovascular, with the device category listed as Embolization Agent, Vascular. No supplement type or supplement reason is present, so the record does not state whether this decision relates to an original PMA or a later change. The statement reports an intended use only; it does not provide independent evidence of safety or clinical effectiveness.

FDA approval order statement

The Embrace Hydrogel Embolic System (HES) is indicated for embolization of hypervascular tumors in peripheral arteries ? 5mm.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 5, 2025

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250003
Regulatory pathway
Premarket approval application
Product code
QVG
Decision code
APPR
Decision date
Aug 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250003 received

    Application receipt date recorded by FDA.

  2. P250003 · FDA decision

    APPR

  3. P250003/S009 · Related supplement

    Embrace Hydrogel Embolic System

  4. P250003/S010 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  5. P250003/S008 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  6. P250003/S011 · Related supplement

    Embrace Hydrogel Embolic System

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records